Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


J&J Expects Persistent Pricing Pressure Into 2019

CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency and value-based health care. The company's net drug prices declined more than 6% in 2018, he added.

Sales & Earnings Pricing Strategies Pricing Debate

Full Steam Ahead At Ferring To Unlock Microbiome Potential For Reproduction

The Swiss group is expanding its alliance with the Karolinska Institutet to conduct 10 studies designed to improve understanding of the microbiome’s impact on reproductive and gut health challenges.

Deals Clinical Trials Gynecology & Urology

Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie

Johnson & Johnson has solid growth drivers in pharmaceuticals, but still faces an overhang related to talc controversy; Bristol's call will be dominated by the just-announced Celgene acquisition; and AbbVie will face questions about its cancer plans after expensive failure with Rova-T.

Sales & Earnings Companies Business Strategies
Advertisement


 Recent Tweets from Scrip


Factoring the "What Ifs" into Supply Forecasting

With the pressure on to deliver new products faster and more efficiently, sponsors are facing a variety of challenges. Download this whitepaper and discover the challenges as well as aspects to consider when developing a supply plan, the influence of early decisions and much more.

Read Now

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

 

Commercial Explore this Topic

Set Alert for Commercial

Sun Firefights Governance Concerns

Sun has promised to implement certain changes to address corporate governance concerns that have riled investors, including “unwinding” a loan transaction and doing away with a controversial related party arrangement for domestic sales. But will that be enough for markets to "forget" allegations of lapses or "re-rate" the firm any time soon?

Commercial Companies India

Biotech Showcase 2019: Mimicking plants creates GI infection antibiotic alternative

Gastrointestinal infections are the number one reason for US physician visits and account for about half the $50bn in global antibiotic sales. Speaking during Biotech Showcase 2019, Alex Huang, CEO of Quellthera, described to Mike Ward how the company is developing a novel prodrug concept, which mimics plant hypersensitive responses to toxins, as a sustainable alternative to antibiotics and as an adjunctive therapy to standard of care antibiotics for treatment and prophylaxis for a range of GI infections.

Infectious Diseases Companies Research & Development

GSK Looks For New Chair To Lead It Through New Strategic Direction

GSK’s non-exec chairman steps down from the UK firm, just a month after announcing a split that will reshape the company.

Companies Leadership

Molecule Diversity Creates Developmental Challenges For Aspiring Commercial Biotechs

Speaking on the sidelines at BIO-Europe 2018, Jenifer Wheat, head of commercial development at Lonza’s mammalian and microbial MMBU, explains to Scrip how having a manufacturing component in their commercialization strategies can facilitate success. Even those companies not planning to launch their own products but planning to license programs to partners can benefit from support from the contract development manufacturing sector.

Strategy Manufacturing

Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout

Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.

Business Strategies Commercial

Aum Bets On Asia-To-Global Oncology Model

Emerging Company Profile: Singapore-based Aum Biosciences hopes to disrupt early stage oncology drug development with an Asia-pivoted model, and the fledgling firm has struck interesting alliances to progress its plans.
Singapore StartUps and SMEs

Dark Days For Sun As Governance Saga Escalates

Allegations of corporate governance lapses continued to singe Sun, but there is little clarity on which way things are headed, at least for now.

Commercial Companies

Catalan Biotechs Boosted By International Backers

The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.

Spain Financing

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Rare But Real: How One Startup Is Willing Itself To Lift China Orphan Drug Market

As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.

China Rare Diseases Policy & Regulation

Financial Transparency Concerns Over Patient Groups Advising NICE

England and Wales' cost-effectiveness agency has been urged to review its disclosure policy in a BMJ report which calls on NICE to probe the financial transparency of patient organizations that contribute to reimbursement assessments.

Reimbursement United Kingdom

Pharma Industry Holds Tight As Disorderly Brexit Approaches

A worst-case Brexit scenario – a disorderly one – has become more likely, making an already white-knuckled life sciences industry step up its preparations.

Brexit Trade

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants surveyed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies

Research & Development Explore this Topic

Set Alert for Research & Development

Aurinia’s Voclosporin Misses Superior Tolerability Vs. Restasis, But Pushes On In Drug Eye

Aurinia's voclosporin missed the primary endpoint of superior tolerability compared to Restasis, but hit objective secondary efficacy endpoints that that may better position it for approval in dry eye.

Research & Development Clinical Trials Ophthalmic

Bone Therapeutics Cracks On With Allogeneic Cells For Spinal Fusion, Broken Bones

2019 should see top-line clinical results for Bone Therapeutics' off-the-shelf cell therapy for spinal fusion procedures.

Regenerative Medicine Orthopedics

TaiwanJ To Progress Liver Drug JKB-122 In AIH After Good Phase II Data

Taiwanese speciality pharma TaiwanJ said its Phase II orphan drug designation study of investigational therapy JKB-122 in autoimmune hepatitis met both the primary and secondary endpoints.

Liver & Hepatic Clinical Trials

Revamped Redx’s New CEO Says Porcupine Inhibitor Trials 'Now On Track'

After regulatory talks, revamped Redx gets green light to resume clinical study of RXC004 in patients with advanced solid tumors, while sister porcupine inhibitor RXC006 is set to enter IPF trials in 2020, the biotech's CEO tells Scrip.

Clinical Trials Cancer
UsernamePublicRestriction

Register

Advertisement